CABA Stock - Cabaletta Bio, Inc.
Unlock GoAI Insights for CABA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-4,813,000 | $-1,426,000 | $-3,684,000 | $-733,000 | $-354,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-125,141,000 | $-74,660,000 | $-54,139,000 | $-46,313,000 | $-33,833,000 |
| Net Income | $-115,864,000 | $-67,675,000 | $-52,975,000 | $-46,289,000 | $-33,339,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.34 | $-1.65 | $-1.81 | $-1.80 | $-1.44 |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Visit WebsiteEarnings History & Surprises
CABAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.45 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.49 | $-0.44 | +10.2% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.71 | $-0.73 | -2.8% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.67 | $-0.71 | -6.0% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-0.65 | $-0.65 | 0.0% | = MET |
Q4 2024 | Nov 14, 2024 | $-0.59 | $-0.62 | -5.1% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.55 | $-0.56 | -1.8% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.48 | $-0.51 | -6.3% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.39 | $-0.46 | -17.9% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.39 | $-0.37 | +5.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.47 | $-0.37 | +21.3% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.48 | $-0.45 | +6.2% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.47 | $-0.52 | -10.6% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.49 | $-0.39 | +20.4% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.52 | $-0.45 | +13.5% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.64 | $-0.45 | +29.7% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.68 | $-0.49 | +27.9% | ✓ BEAT |
Q4 2021 | Nov 1, 2021 | $-0.52 | $-0.45 | +13.5% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.51 | $-0.45 | +11.8% | ✓ BEAT |
Q2 2021 | May 3, 2021 | $-0.49 | $-0.41 | +16.3% | ✓ BEAT |
Latest News
Frequently Asked Questions about CABA
What is CABA's current stock price?
What is the analyst price target for CABA?
What sector is Cabaletta Bio, Inc. in?
What is CABA's market cap?
Does CABA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CABA for comparison